What question did this study set out to answer?

The aim is to evaluate the safety and effects of YAQ007 on ammonia levels in cirrhosis.

April 5, 2026Hepatology1 citations

A randomized, open-label, Phase 2a study to assess the safety, pharmacodynamics, and pharmacokinetics of YAQ007 versus rifaximin in cirrhosis

MBMaría Pilar Ballester JCJuan Antonio Carbonell-Asins AEAhmed Elshabrawi

Key Points

The aim is to evaluate the safety and effects of YAQ007 on ammonia levels in cirrhosis.
Phase 2a randomized open-label design
Comparison of YAQ007 and rifaximin
Doses of YAQ007 were ≥4 g BID
YAQ007 showed short-term ammonia-lowering activity
Results suggest potential for further clinical evaluation
Findings are exploratory and hypothesis-generating

Abstract

In this Phase 2a study, oral YAQ007 demonstrated short-term ammonia-lowering activity at doses ≥4 g BID. Given the exploratory design, these findings are hypothesis-generating and support further clinical evaluation.

问 AI

Bookmark

View Full Paper

Cite This Study

Ballester et al. (Fri,) studied this question.

synapsesocial.com/papers/69d1fde4a79560c99a0a446d https://doi.org/https://doi.org/10.1097/hep.0000000000001748

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

问 AI

Bookmark

View Full Paper